Glaucoma Treatment Market to Grow to $3bn by 2023
October 19, 2015.
The treatment market for glaucoma will rise in value from $2.4 billion in 2013 to approximately $3 billion by 2023 across the seven major markets (7MM) of the US, France, Germany, Italy, Spain, UK, and Japan, according to a new report. The growth represents a moderate overall CAGR of 2.4%.
EpiCast Report: Glaucoma: Epidemiology Forecast to 2023 states that growth will be driven by the arrival of innovative first-in-class drugs, such as Rhopressa/Roclatan, Vesneo, and trabodenoson, and the introduction of additional fixed-dose combination (FDC) products, such as Tapcom/Taptiqom and Simbrinza, during the forecast period.
Changing population demographics in the 7MM is contributing to the increase in the number of cases of glaucoma; however, the report argues, further epidemiological research is needed as there is a paucity of national and international data evaluating the prevalence and trends of glaucoma worldwide.
Is Artificial Intelligence a ‘Product’? Products Liability Implications for AI-Based Products
April 10th 2025As the physical products we use evolve to become increasingly complex, traditional products liability frameworks may not always fit to provide remedies for harm that can result from using novel product types.
